Article Text

other Versions

Download PDFPDF
The Cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA Study
  1. Andrew Briggs (a.briggs{at}
  1. University of Glasgow, United Kingdom
    1. Borislava Mihaylova
    1. University of Oxford, United Kingdom
      1. Mark Sculpher
      1. University of York, United Kingdom
        1. Alistair Hall
        1. University of Leeds, United Kingdom
          1. Jane Wolstenholme
          1. University of Glasgow, United Kingdom
            1. Maarten Simoons
            1. Erasmus University Medical Centre, Netherlands
              1. Jaap Deckers
              1. Erasmus University Medical Centre, Netherlands
                1. Ferrari Roberto
                1. University of Ferrara, Italy
                  1. Willem J Remme
                  1. Sticares Cardiovascular Research Institute, Netherlands
                    1. Michel Bertrand
                    1. Hopital Cardiologique de Lille, France
                      1. Kim Fox
                      1. Royal Brompton Hospital, United Kingdom


                        Objectives The aim of this study is to assess the cost-effectiveness of perindopril in stable coronary heart disease in the UK

                        Background The European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported.

                        Methods Clinical and resource use data were taken from the EUROPA trial. Costs included medications and hospitalisations. Health-related quality of life values were taken from external sources. Cost-effectiveness analysis is presented as a function of the risk of a primary event (non-fatal myocardial infarction, cardiac arrest or cardiovascular death) in order to identify individuals for whom treatment offers greatest value for money.

                        Results The median incremental cost per QALY gained of perindopril across the heterogeneous population of EUROPA was estimated as 9,700 GBP (inter-quartile range: 6,400 GBP - 14,200 GBP). Overall, 88% of the EUROPA population had an estimated cost per QALY below 20,000 GBP and 97% below 30,000 GBP. For a threshold value of cost-effectiveness of 30,000 GBP per QALY gained, individuals representing the 25th, 50th (median) and 75th percentiles of the cost-effectiveness distribution for perindopril have probabilities of 0.999, 0.99 and 0.93 of being cost-effective, respectively. Cost-effectiveness was strongly related to higher risk of a primary event under standard care.

                        Conclusions Whether the use of perindopril can be considered cost-effective depends on the health care systems' threshold value of cost-effectiveness. For the large majority of patients included in EUROPA, the incremental cost per QALY gained is lower than the apparent threshold used by the National Institute for Health and Clinical Excellence in the UK.

                        • Cost-effectiveness analysis
                        • cardiovascular diseases
                        • hypertension

                        Statistics from

                        Request Permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                        Supplementary materials

                        Linked Articles

                        • Editorial
                          Milan Gupta Subodh Verma G B John Mancini